(Q33653602)

28 July 2017

1 reference

title

Prostate-specific antigen and other markers of therapeutic response (English)

1 reference

28 July 2017

Carducci MA

1

1 reference

28 July 2017

DeWeese TL

series ordinal

2

1 reference

28 July 2017

Nelson JB

series ordinal

3

1 reference

28 July 2017

publication date

1 May 1999

1 reference

Urologic Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

26

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

291-302, viii

1 reference

Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Effect of prolactin on the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Granins and prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

1 reference

7 January 2021

Conformal mixed neutron and photon irradiation in localized and locally advanced prostate cancer: preliminary estimates of the therapeutic ratio

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Clinical utility of serum osteocalcin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Serial tissue polypeptide specific antigen determination in the followup of hormone treated carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Serum levels of endothelial and neural cell adhesion molecules in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

High serum prolactin associated with poor prognosis in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Serum basic fibroblast growth factor in men with and without prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Total and regional bone mass and biochemical markers of bone remodeling in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

THE USE OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE END POINT IN THE TREATMENT OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Acid phosphatase: defining a role in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Plasma osteocalcin values and related hormonal parameters in patients subjected to a variety of prostate anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Interleukin-6: a candidate mediator of human prostate cancer morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Clinical Significance of Serum Alkaline Phosphatase Isoenzyme Levels in Advanced Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Endothelin-1 production and agonist activities in cultured prostate-derived cells: implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970069-0

7 January 2021

10.1016/S0094-0143(05)70069-0

Identifiers

DOI

1 reference

28 July 2017

1 reference